On Friday, Candel Therapeutics Inc (NASDAQ: CADL) opened lower -31.12% from the last session, before settling in for the closing price of $9.80. Price fluctuations for CADL have ranged from $1.02 to $14.60 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company slipped by -25.00% over the past five years. Company’s average yearly earnings per share was noted -25.95% at the time writing. With a float of $20.29 million, this company’s outstanding shares have now reached $32.13 million.
Let’s look at the performance matrix of the company that is accounted for 42 employees. In terms of profitability, gross margin is 54.28%, operating margin of -2001.58%, and the pretax margin is -2939.13%.
Candel Therapeutics Inc (CADL) Insider Updates
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Candel Therapeutics Inc is 37.53%, while institutional ownership is 14.78%. The most recent insider transaction that took place on Nov 29 ’24, was worth 92,898. In this transaction Chief Technology Officer of this company sold 20,392 shares at a rate of $4.56, taking the stock ownership to the 125,657 shares. Before that another transaction happened on Nov 29 ’24, when Company’s Chief Executive Officer sold 48,847 for $4.56, making the entire transaction worth $222,527. This insider now owns 294,788 shares in total.
Candel Therapeutics Inc (CADL) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -25.95% per share during the next fiscal year.
Candel Therapeutics Inc (NASDAQ: CADL) Trading Performance Indicators
Check out the current performance indicators for Candel Therapeutics Inc (CADL). In the past quarter, the stock posted a quick ratio of 1.18.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.74, a number that is poised to hit -0.30 in the next quarter and is forecasted to reach 0.15 in one year’s time.
Technical Analysis of Candel Therapeutics Inc (CADL)
Candel Therapeutics Inc (NASDAQ: CADL) saw its 5-day average volume 30.18 million, a positive change from its year-to-date volume of 2.34 million. As of the previous 9 days, the stock’s Stochastic %D was 37.02%. Additionally, its Average True Range was 1.47.
During the past 100 days, Candel Therapeutics Inc’s (CADL) raw stochastic average was set at 27.42%, which indicates a significant increase from 23.93% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 297.11% in the past 14 days, which was higher than the 130.83% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $5.35, while its 200-day Moving Average is $5.95. Nevertheless, the first resistance level for the watch stands at $7.19 in the near term. At $7.64, the stock is likely to face the second major resistance level. The third major resistance level sits at $8.13. If the price goes on to break the first support level at $6.25, it is likely to go to the next support level at $5.76. Assuming the price breaks the second support level, the third support level stands at $5.31.
Candel Therapeutics Inc (NASDAQ: CADL) Key Stats
There are currently 32,476K shares outstanding in the company with a market cap of 150.99 million. Presently, the company’s annual sales total 0 K according to its annual income of -37,940 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -10,650 K.
